An advisory committee has recommended approval in the European Union of marstacimab for severe hemophilia A or B patients without inhibitors.

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...